Proteome and Phosphoproteome Changes Associated with Prognosis in Acute Myeloid Leukemia by Aasebø, Elise et al.
cancers
Article
Proteome and Phosphoproteome Changes Associated
with Prognosis in Acute Myeloid Leukemia
Elise Aasebø 1,2 , Frode S. Berven 2,3, Sushma Bartaula-Brevik 1, Tomasz Stokowy 1,4 ,
Randi Hovland 4,5, Marc Vaudel 1, Stein Ove Døskeland 3, Emmet McCormack 6,
Tanveer S. Batth 7, Jesper V. Olsen 7, Øystein Bruserud 1, Frode Selheim 2,3,† and
Maria Hernandez-Valladares 1,2,*,†
1 Department of Clinical Science, University of Bergen, 5021 Bergen, Norway; Elise.Aasebo@uib.no (E.A.);
Sushma.Bartaula@uib.no (S.B.-B.); Tomasz.Stokowy@uib.no (T.S.); Marc.Vaudel@uib.no (M.V.);
Oystein.Bruserud@uib.no (Ø.B.)
2 The Proteomics Facility of the University of Bergen (PROBE), University of Bergen, 5009 Bergen, Norway;
Frode.Berven@uib.no (F.S.B.); Frode.Selheim@uib.no (F.S.)
3 The Department of Biomedicine, University of Bergen, 5009 Bergen, Norway; stein.doskeland@uib.no
4 Department for Medical Genetics, Haukeland University Hospital, 5021 Bergen, Norway;
Randi.Hovland@uib.no
5 Department of Biological Sciences, University of Bergen, 5006 Bergen, Norway
6 Centre for Cancer Biomarkers, Department of Clinical Science, University of Bergen, 5021 Bergen, Norway;
Emmet.Mc.Cormack@uib.no
7 Novo Nordisk Foundation Center for Protein Research, University of Copenhagen,
2200 Copenhagen, Denmark; t.batth@cpr.ku.dk (T.S.B.); jesper.olsen@cpr.ku.dk (J.V.O.)
* Correspondence: Maria.Hernandez-Valladares@uib.no; Tel.: +47-5558-6368
† F.S. and M.H.-V. share last authorship.
Received: 4 February 2020; Accepted: 13 March 2020; Published: 17 March 2020


Abstract: Acute myeloid leukemia (AML) is a hematological cancer that mainly affects the elderly.
Although complete remission (CR) is achieved for the majority of the patients after induction and
consolidation therapies, nearly two-thirds relapse within a short interval. Understanding biological
factors that determine relapse has become of major clinical interest in AML. We utilized liquid
chromatography tandem mass spectrometry (LC-MS/MS) to identify the protein changes and protein
phosphorylation events associated with AML relapse in primary cells from 41 AML patients at
time of diagnosis. Patients were defined as relapse-free if they had not relapsed within a five-year
clinical follow-up after AML diagnosis. Relapse was associated with increased expression of RNA
processing proteins and decreased expression of V-ATPase proteins. We also observed an increase in
phosphorylation events catalyzed by cyclin-dependent kinases (CDKs) and casein kinase 2 (CSK2).
The biological relevance of the proteome findings was supported by cell proliferation assays using
inhibitors of V-ATPase (bafilomycin), CSK2 (CX-4945), CDK4/6 (abemaciclib) and CDK2/7/9 (SNS-032).
While bafilomycin preferentially inhibited the cells from relapse patients, the kinase inhibitors were
less efficient in these cells. This suggests that therapy against the upregulated kinases could also
target the factors inducing their upregulation rather than their activity. This study, therefore, presents
markers that could help predict AML relapse and direct therapeutic strategies.
Keywords: acute myeloid leukemia; proteome; phosphoproteome; kinase; V-ATPase; markers;
patient relapse; mass spectrometry
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1. Introduction
Acute myeloid leukemia (AML) is an aggressive and heterogeneous malignancy, the two main
subsets being acute promyelocytic leukemia (APL) and the heterogenous group non-APL AML [1,2].
The APL variant is described by a characteristic clinical picture, specific cytogenetic abnormalities,
different treatment than the other non-APL variants and a favorable prognosis [3]. In this article, we
will use the term AML to refer to the non-APL variants of the disease, and these variants are also
highly heterogeneous regarding genetic abnormalities and prognosis (i.e., relapse-free survival), with a
median age at the time of first diagnosis of 65–70 years [4]. Despite the heterogeneity of the non-APL
variants, these patients are treated according to the same guidelines, both with regard to intensive
and potentially curative treatment (possibly including stem cell transplantation) for the young and fit
subset of patients and less intensive leukemia-stabilizing treatment for elderly (i.e., above 70–74 years
of age) or unfit patients [4–6]. Most patients receiving intensive anti-AML treatment achieve initial
disease control (i.e., complete hematological remission), but a major cause of death is due to primary
resistance and chemoresistant leukemia relapse either during or following the chemotherapy [4,5,7].
The overall long-term AML free survival, even for young and fit AML patients, is therefore only
approximately 50% [8]. Thus, there is a need for a better prognostic classification and therapeutic
strategies both for the younger patients receiving intensive therapy and for the large majority of elderly
or unfit patients receiving leukemia-stabilizing therapy.
Even though previous studies have detected associations between prognosis and the
phosphorylation status of selected intracellular mediators [9,10], only cytogenetic abnormalities and
submicroscopic mutations of certain genes (e.g., in CEBPA, FLT3, NPM1 and TP53) are implemented in
the routine prognostic evaluation and risk adapted treatment of AML patients procedures [8,11–15].
However, the underlying of AML relapse determinants remains elusive, as most of the late relapse
cases are associated with a normal karyotype or with the absence of typical cytogenetic abnormalities
observed in therapy-related AML [16,17]. Mutations in NPM1 and in signaling genes such as NRAS,
KIT and PTPN11 are frequently observed at time of diagnosis but are less found at relapse [18,19].
However, FLT3-ITDs and mutations in WT1, KDM6A and RUNX1 are often found at relapse [8,20].
Although epigenetic regulation might be necessary for the development of relapse, regulators of DNA
methylation and of chromatin remodeling as well as histone modifiers show different evolutionary
patterns from diagnosis to relapse stages [21]. A separate longitudinal genomic characterization has
shown that in 80% of the patients, the founder leukemic clone survived chemotherapy and provide a
basis for late relapse [22].
Liquid chromatography tandem mass spectrometry (LC-MS/MS)-based proteomics or
phosphoproteomics have been utilized for the subclassification of patients with non-APL variants
of AML [23–25] and for the study of proteins released by apoptosis-resistant and sensitive primary
AML cells [26]. Remarkable advances in the mass spectrometry technology over the past decades
have provided equipment with optimized resolution, allowing high coverage characterizations of
post-translation modifications (PTMs). Thus, predictive phosphorylation markers for the treatment of
AML with FLT3 inhibitor quizartinib, the description of the phosphotyrosine-proteome, tyrosine-kinome
and tyrosine-phosphatome in AML, and the identification of sensitivity determinants of AML cells to
kinase inhibitors have been recently described [27–29].
We previously showed that a super-SILAC (Stable Isotope Labeling with Amino Acids in Cell
Culture) mix based on five AML cell lines provided a solid reference for quantitative proteomics
studies of AML patient cells [30]. Together with optimized sample preparation and phosphopeptide
enrichment protocols, our proteomics workflows proved to be useful for the study of prognosis
biomarkers and treatment response in AML [31–33].
In the present population based-study, in order to identify relapse promoters at diagnosis, we
compared the proteome and phosphoproteome profiles of pretreatment AML cells collected at the time
of diagnosis for patients who later became long-term leukemia-free survivors (at least 5 years AML-free
survival), or had a primary resistant disease, or suffered from a chemoresistant relapse after completing
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the planned intensive therapy. Based on the proteomics and phosphoproteomics analysis of these
two groups, we found common denominators in pretreatment samples such as RNA processing and
V-ATPase proteins, that should be further investigated as potential prognostic biomarkers or possible
therapeutic targets.
2. Results
2.1. AML Patients Included in the Study
To study the proteome and phosphoproteome changes between chemoresistant/relapse (RELAPSE)
and relapse-free (REL_FREE) patients at the time of first diagnosis, we selected 41 patient samples, as
illustrated in Figure 1a,b. The main characteristics of our patient cohort are given in Table 1 and Table S1.
As expected, approximately half of the 41 patients showed a normal karyotype (22 out of 36 investigated
patients); the most common mutations were on NPM1 and FLT3-ITD (Table S1). Furthermore, when
analyzing the whole patient cohort, NPM1 mutations showed significant correlations both with
morphological signs of AML cell differentiation (especially FAB M4/M5; Fischer’s exact test, p = 0.023)
and DNA methylation gene mutations (p = 0.003). All these observations are consistent with
observations previously described for AML in general [4,12–14]. Finally, the percentage of bone
marrow AML blasts did not differ between the two subsets (p = 0.247).
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Figure 1. Overview of the RELAPSE and REL_FREE ML patient cohort and the orkflows for the
proteome and phosphoproteome analysis of acute myeloid leukemia (AML) patient cells. (a) The study
included AML cell samples from 26 RELAPSE and 15 REL_FREE patients collected at the time of first
diagnosis. All patients received intensive induction chemotherapy, consolidation th rapy an achieved
complete remission (CR), as described in Materials a d Methods. Patients were classified after an
observation time of at least five years from the initial therapy. (b) Survival plot for the patients included
in each group. Dashed line indicates the five-years observation time. (c) AML sample preparation steps
for proteome and phosphoproteome analysis include blood extraction, blast isolation, cell lysis, addition
of super-SILAC (Stable Isotope Labeling wit Amino Acids i Cell Cultur ) mix, filter-aided sample
preparation (FASP)-based protein digestion and additional immobilized metal affinity chromatography
(IMAC) enrichment of phosphopeptides. After liquid chromatography tandem mass spectrometry
(LC-MS/MS) acquisition, our proteomic workflow ends with bio-computation and validation analyses.
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Table 1. Characteristics of the 41 AML patients used in the study at the first time of diagnosis.
Characteristic REL_FREE RELAPSE
Age average (range) in years 49.5 (36–65) 50.5 (18–68)














FAB: French-American-British; WT: wild type; ITD: internal tandem duplication; Ins: a 4 bp-insertion/duplication;
ND indicates not determined
Patients with and without relapse showed expected differences in the frequencies of favorable
NPM1 mutations (increased in REL_FREE patients) and adverse FLT3-ITD (increased in RELAPSE
patients) [8]. Furthermore, REL_FREE patients also showed a high frequency of monocytic
differentiation by their leukemic cells (i.e., FAB M4/M5), that was significantly different from the
RELAPSE patients (Fischer’s exact test, p = 0.003). This is mainly due to the expected and significant
association between NPM1 mutations and morphological signs of differentiation (i.e., low frequency of
FAB M0/M1 and high frequency especially of M4/M5; Fischer’s exact test, p = 0.023) but one inv(16)
patient with expected M4 morphology also contributed. Previous studies have also described an
association between NPM1 mutations and morphological signs of differentiation and expression of
the CD33 differentiation marker, as well as an inverse correlation with expression of the CD34 stem
cell marker [34,35]. Thus, all observations described above are expected and can be explained by
previously described characteristics of AML patient subsets in large AML studies.
2.2. The Protein Abundances of rRNA Processing Proteins and V-ATPase Subunits Differ Between RELAPSE
and REL_FREE Patients
We compared the proteome profiles of AML cells derived from 26 RELAPSE and 15 REL_FREE
patients at the time of diagnosis, obtained according to our filter-aided sample preparation (FASP)-based
workflow (Figure 1c). We quantified 6781 proteins, of which 5309 had a quantitative value in at least
five patients in each group. The t-test based statistical analysis resulted in 351 differentially expressed
proteins; 210 proteins were upregulated and 141 were downregulated in the RELAPSE relative to
REL_FREE group (Supplementary file 1). The proteome of patient-derived cell lysates was also
processed and quantified using label-free quantification (LFQ), for validating the super-SILAC based
proteome quantitation (Supplementary data, Figure S1, Figure S2, Figure S3 and Supplementary file 1).
The RELAPSE vs. REL_FREE fold changes (FCs) of the 4041 proteins quantified in both experiments
had good correlation (Pearson R = 0.72; Figure S2).
Hierarchical clustering of the 351 differential proteins grouped the patients into two main
clusters (Figure 2a), which corresponded to the RELAPSE and REL_FREE samples, although a
distinct separation was not obtained. Gene ontology (GO) enrichment analysis showed that ATPase
activity (coupled to transmembrane movement of ions, rotational mechanism), proton-exporting
ATPase activity, phagosome acidification and iron ion transport (Figure 2b) were more abundant
processes in the REL_FREE patients. These terms include proteins of the vacuolar (V)-H+-ATPase, an
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ATP-dependent proton pump in cellular membranes, such as lysosomes and endosomes [36]. The
proteins enriched in this group were primarily located in the cytosol or extracellular organelles, such as
vesicles. In contrast, proteins involved in ribosomal processes, such as rRNA metabolic process, ncRNA
processing and ribonucleoprotein complex biogenesis were clearly higher in the RELAPSE patients,
where 46% of the increased proteins were annotated to the nucleolus in the cellular compartment
analysis (Figure 2b).
Moreover, a protein-protein interaction (PPI) network of the differentially expressed proteins
(Figure 2c) confirmed the increased abundance of proteins involved in rRNA processing and ribosome
biogenesis in relapsed patients (cluster 1; 69 proteins). RRP1B (p < 0.0002, FC 1.09) and AATF
(p < 0.0002, FC 0.91) were the most significant proteins in this cluster. AATF (also known as CHE1)
participates in several cellular pathways, such as 40S ribosomal subunit synthesis in complex with
NGDN (p = 0.0014, FC 0.95) and NOL10 (p = 0.0007, FC 0.85) [37], and high AATF expression has been
linked to variants of leukemia [38,39]. Other proteins in this cluster were CEBPZ, a transcription factor
in the CEBP family, several WD repeat-containing proteins (e.g., WDR3, WDR18, WDR36), probable
ATP-dependent RNA helicases (e.g., DDX18, DDX27, DDX56) and members of the C/D box small
nucleolar ribonucleoprotein (snoRNP) complex (NOP56 and NOP58), which guides 2’O methylation
of the rRNA. Proteins involved in neutrophil degranulation dominated cluster 2 and nine subunits
belonging to the V-ATPase complex were identified in cluster 3 (Figure 2c), all with higher abundance
in the REL_FREE patients. Regulated V-ATPase subunits (cluster 3) and proteins participating in rRNA
processing and ribosomal biogenesis (cluster 1) are detailed in Supplementary file 2. Cluster 4 and 5
contained proteins involved in chromatin remodeling and RNA polymerase I subunits, respectively,
which were upregulated in the RELAPSE patients.
The gene set enrichment analysis (GSEA) against the Hallmark gene set collection,
conducted to identify classes of genes overrepresented in the complete dataset, resulted in
HALLMARK_MYC_TARGETS_V2 (systematic name: M5928), as the only significant gene set
(false discovery rate, FDR, q-value = 0.046) (Figure S4). This gene set was upregulated in the RELAPSE
group and consisted of 58 genes [40]. A total of 15 out of the 30 proteins who contributed most to the
gene set enrichment results (i.e. the leading edge subset) were found in cluster 1 in Figure 2c.
Using the data on time from diagnosis to relapse (Table S1), we further classified the RELAPSE
patients into two groups: 14 EARLY RELAPSE and 12 LATE RELAPSE patients with first relapse
occurring before and at/after 12 months from diagnosis, respectively, in alignment with reported
remission duration [41,42]. We found 236 and 295 differentially expressed proteins in the EARLY
RELAPSE vs. REL_FREE and in the LATE RELAPSE vs. REL_FREE comparisons, respectively. One
hundred and twelve regulated proteins from each set overlapped and some of these belonged to the
ribosome biogenesis RNA processing, the DNA-directed RNA polymerase and V-ATPase clusters
that we identified when we analyzed all the RELAPSE patients together (Figure S5, Figure 2c). Thus,
although the EARLY and LATE RELAPSE proteomes might show some features related to the different
relapse timings, regulation of relevant protein networks were observed in all relapsed patients.
2.3. Differential CDK, CSK2 and PRKCA/D Kinase Activities between RELAPSE and REL_FREE Patients
We constructed a dataset comprising 12,309 identified and quantified class I protein
phosphorylation sites from 3003 proteins of 26 RELAPSE and 15 REL_FREE patients. Serine
phosphorylation made up the majority of the identified phosphosites (89.7%) while phosphorylation
on threonine and tyrosine (10.0% and 0.3%, respectively) comprised the rest. We identified 274
differentially regulated phosphorylated sites based on a statistical analysis of 5634 phosphosites, which
were quantified in at least five patients in each group (Supplementary file 3).
Hierarchical clustering using these 274 phosphosites divided the phosphoproteome of RELAPSE
and REL_FREE patients (Figure 3a). Two clusters, one containing 138 phosphosites and another
with 136 phosphosites, were upregulated and downregulated in the RELAPSE, relative to REL_FREE
patients, respectively (Supplementary file 3).
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Figure 2. The global AML cell proteome shows increased abundance of rRNA processing proteins and
decreased abundance of V-ATPase subunits for patients who relapse. (a) Hierarchical clustering of the
patients (P1-P53), based on protein expression (SILAC log2 ratio) of the 351 proteins with significantly
different regulation in AML cells from REL_FREE (g e n) and RELAPSE (purple) patients. Two vertical
main clusters were observed, one dominated by proteins with higher abundance in mostly REL_FREE
patients (Cluster UP_REL_FREE) and the other by proteins with higher abundance in RELAPSE patients
(Cluster UP_RELAPSE). (b) Gene ontology (GO) analyses of the two protein clusters identified in
Figure 2a were performed, to reveal enriched biological processes (BP; see the right side of the figure),
cellular compartments (CC) and molecular functions (MF) in the two protein clusters. The upper part
of the figure corresponds to the upper REL_FREE cluster identified in Figure 2a, whereas the lower
part of the figure corresponds to the lower RELAPSE cluster. The various enriched GO terms are listed
in the left part of the figure. The number of proteins associated to a specific GO term (count) and the
corresponding –log10 false discovery rate (FDR) of these top significant GO terms are shown on the
x-axis. *The complete name of the GO term referred to as ATPase activity in the figure is “ATPase
activity, coupled to transmembrane movement of ions, rotational mechanism”. (c) Protein–protein
interactions (PPI) networks of the 351 proteins from the STRING database, visualized and analyzed with
Cytoscape and ClusterONE, respectively. The five clusters with highest significance of cohesiveness
are shown with p values of a one-sided Mann–Whitney U test. The protein nodes are colored according
to their RELAPSE/REL_FREE log2 fold change (FC), i.e., purple indicates increased abundance in the
RELAPSE group and green increased abundance in the REL_FREE group. Protein nodes with black
border represent significantly regulated proteins found in both the SILAC and label-free datasets.
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Figure 3. The AML RELAPSE phosphoproteome is enriched in cyclin-dependent kinase (CDK) substrates
and RNA processing casein kinase 2 (CSK2) targets. (a) Hierarchical clustering of 274 differentially
regulated phosphorylation sites revealed two clusters: HP (High Phosphorylation)_RELAPSE (in purple)
and HP_REL_FREE (in gre n). The SILAC log2 ratio scale and color code is also shown. (b) GO
analyses of the two phosphoprotein clusters identified in Figure 3a were performed to reveal enriched
BP, indicated to the right in the figure, CC and MF. The GO terms are listed in the left part of the
figure; the upper part of the figure corresponds to the upper RELAPSE cluster identified in Figure 3a
whereas the lower part of the fi ure corresponds to the lower REL_FREE cluster. The x-axis indicates
the number of pho phoproteins/FDR. (c) Sequence mot analysis of the ± six amino acids, flanking
the differentially regulated phosphorylation sites for either cluster. (d) Kinase-substrate enrichment
analysis (KSEA) of differentially regulated and unregulated phosphorylation sites. The kinase z-score
(X axis) is the normalized score for each kinase (Y axis), weighted by the number of identified substrates.
(e) Networks of PPI based on STRING database and visualized in Cytoscape after ClusterONE analysis.
Significance of networks of high cohesiveness is shown with the p value of a one-sided Mann–Whitney
U test. The differentially regulated phosphorylation site(s) is shown next to each protein. FC of
phosphorylation are color-coded; purple-colored proteins showed a higher phosphorylation in the
RELAPSE group and green-colored proteins showed a higher phosphorylation in the REL_FREE group.
Kinases are specifically distinguished using hexagon shapes.
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Cellular component GO analysis revealed an enrichment of upregulated nuclear phosphoproteins
for RELAPSE patients, whereas cytoplasm, cytosol, membranes and vacuolar structures were enriched
in the REL_FREE group (Figure 3b). Immune effector process, myeloid leukocyte activation and GTPase
binding were the biological processes and molecular functional GO terms enriched in this group.
To identify protein kinases differentially activated in the two groups, we performed a
phosphorylation site motif analysis (IceLogo) [43]. We found a strong bias towards acidic amino
acids such as glutamic acid (E), in close proximity to the differentially phosphorylated sites in
the RELAPSE group when compared to the unregulated phosphosites (Figure S6a), suggesting a
higher casein kinase 2 (CSK2) activity in this group. Using differentially phosphorylated sites in
the REL_FREE group, the analysis identified a basophilic KXpS/pT motif, suggesting a moderate
activation of protein kinase C types, PRKCA and PRKCD (Figure S6b). Moreover, proline-directed
motifs for phosphorylation by mitogen-activated protein kinases (MAPKs) and cyclin-dependent
kinases (CDKs) were underrepresented in the REL_FREE group. When we directly compared
the sequences surrounding the differentially regulated phosphorylation sites in the RELAPSE and
REL_FREE groups, higher CSK2, MAPK and CDK activation was observed in the RELAPSE, and higher
PRKCA/D in the REL_FREE group, confirming the previous motif analysis (Figure 3c, Supplementary
file 4). Furthermore, the kinase-substrate enrichment analysis (KSEA) [44,45], which is based on
phosphorylation FCs to estimate kinase’s activity, confirmed the higher activity of several MAPKs and
CDKs in the RELAPSE group and the higher activity of PRKCA, PRKCD and AKT serine/threonine
kinases in the REL_FREE group (Figure 3d). We found nine phosphosites on six different protein kinases
in the data set of 274 differentially regulated phosphorylation sites. Seven of the nine phosphosites
(including those on PRKCD, PAK2, MAP3K3, BMP2K and NEK7 kinases) were found to be upregulated
in the REL_FREE group relative to the RELAPSE group. In particular, sites on the kinase domain
activation loop of NEK7 (T190 and T191) were more abundant in the REL_FREE group. Conversely,
phosphorylation of the receptor-type tyrosine-protein kinase FLT3 on S759 and S762 was higher in the
RELAPSE group relative to the REL_FREE group.
Several PPI networks of significant cohesiveness were found after a ClusterONE analysis based
on STRING interactions of differentially phosphorylated proteins (Figure 3e). Even if stringent criteria
in STRING was used, we should point out that false positives could occur in the networks. The
most significant network (cluster 1) consisted of ten phosphoproteins with higher phosphorylation
in RELAPSE patients, most of them being RNA binding proteins. A sequence logo analysis [46] of
the amino acids surrounding the 15 phosphosites (corresponding to the ten proteins) suggested a
higher activation of CSK2 in this cluster (Figure S7a). Other significant clusters included DNA binding
proteins (clusters 2 and 4) and proteins involved in nucleic acid metabolism (clusters 3 and 5). A
sequence logo analysis of the amino acids surrounding the phosphosites in clusters 2, 3 and 5 showed
an enrichment of MAPK substrates (Figure S7b–d), although NPM1 S125 in cluster 5 is phosphorylated
by CSK2 [47], and amino acid sequences around HMGN1, LIG1 and LIG3 phosphosites in cluster 4
suggested the involvement of other kinases, such as CSK2 and CDKs [48,49]. Finally, transcription
factor BCL11A, which functions as a myeloid proto-oncogene, and DNA repair protein TP53BP1
showed higher phosphorylation on multiple sites in the RELAPSE group relative to the REL_FREE
group. PPI networks that showed higher phosphorylation in the REL_FREE group were involved in
neutrophil degranulation (cluster 6), membrane organization (cluster 7) and intracellular transport
(cluster 8). Sequence logo analysis of the phosphosite motifs in these clusters suggested a higher
activation of PRKCD/A kinases (Figure S7e–g).
To further elucidate the molecular source of AML relapse in these patients, we utilized the
proteome and phosphoproteome data in order to determine transcription factors responsible for
driving relapse. Specifically, proteins involved in DNA transcription that were regulated at both the
proteome or phosphoproteome level in the RELAPSE group were compared to ChIP-seq data from
the K562 cell line (stored in the ENCODE database), in order to find the potential binding sites of
transcription factors (Table S3). We identified six transcription factors (AFF1, CEBPZ, ETV6, IKZF1,
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PML and TRIM28) that showed the predicted regulation of proteins involved in DNA and RNA
binding proteins, damaged DNA binding proteins, ribosome and carcinogenesis pathways based on
GO molecular function terms and KEGG pathways analysis (Figure S8).
To explain the generally increased phosphosite regulation in the RELAPSE group, we compared
the protein expression to the 274 differentially regulated phosphosites (corresponding to
169 phosphoproteins). We found that 107 (63%) phosphoproteins were not significantly changed
at the protein level (Supplementary file 3). Among them, we noticed all the phosphoproteins of
the DNA repair network (cluster 2) in Figure 3e (Figure S9). In contrast, we spotted 34 proteins
significantly regulated at both protein and phosphosite level, including six phosphoproteins of the
RNA processing network (cluster 1) in Figure 3e (Table S4 and Figure S10). For the majority of these
phosphosites (including FLT3 and PML), the phosphorylation levels correlated closely with their
protein expression levels. Taken together, while RELAPSE AML cells had higher expression of several
phosphorylation-prone proteins, nearly 50% of the differentially regulated phosphorylation sites could
not be explained by protein expression changes, suggesting increased kinase-specific phosphorylation.
In order to study the phosphorylation landscape of early and late relapsed patients separately, we
reanalyzed the phosphoproteome dataset, classifying the RELAPSE into EARLY RELAPSE or LATE
RELAPSE patients, as we did with the proteome dataset. We found 211 and 164 differentially regulated
phosphorylated sites in the EARLY RELAPSE vs. REL_FREE and in the LATE RELAPSE vs. REL_FREE
comparisons, respectively. Only 34 differentially regulated phosphosites were found in both subcohorts
(Figure S11a). A PPI network analysis found components of some of the phosphoprotein clusters
with higher phosphorylation in RELAPSE (clusters 1, 2 and 3) and with higher phosphorylation in
REL_FREE group (clusters 6 and 8), identified when we analyzed all the RELAPSE patients together
(Figure 3e) in the EARLY RELAPSE vs. REL_FREE dataset, whereas a new mixed cluster composed of
RNA metabolism phosphoproteins, transcriptional regulators and SUMOylate target proteins was
found in the LATE RELAPSE vs. REL_FREE dataset (Figure S11b,c). These results showed the
differentiation of phosphorylated signatures in patients with early and late relapse at diagnosis.
2.4. V-ATPase, CSK2, CDK2/7/9 and CDK4/6 Inhibitors Affect the Proliferation of AML Cells
To explore the potential of V-ATPase inhibition in AML, we tested the effect of the V-ATPase
inhibitor bafilomycin A1 (BafA1) in pilot dose-response experiments and observing the growth of AML
cells from four REL_FREE and seven RELAPSE patients, with high or low abundance of V-ATPase
subunits, respectively (Figure S12a). We found non-significant differences in cell viability for RELAPSE
and REL_FREE groups when treated at 10 nM BafA1 and in cell proliferation when treated with 1, 5 and
10 nM BafA1 (Figure 4a,b), although the inhibitor had a smaller effect on proliferation of REL_FREE
cells when used at 10 nM. The proliferation was significantly higher in the untreated control RELAPSE
cells compared to REL_FREE cells (Figure S12b). However, BafA1 at 10 nM decreased significantly
(p = 0.018) the proliferation of cells for most of RELAPSE patients, whereas the proliferation of cells for
three out of four REL_FREE patients was not significantly altered (Figure 4c,d).
In order to further investigate whether the activity of the predicted RELAPSE-activated kinases
was essential for cell survival and proliferation, we tested the proliferation in available AML cells from
ten RELAPSE and nine REL_FREE patients in the presence of inhibitors of CSK2, CDK2/7/9, CDK4/6
and ERK1/2, alone or in combination (Table S5). As shown in Figure 4e, the CSK2 inhibitor CX-4945
at 5000 nM seemed to be slightly more potent inhibitor of REL_FREE cells compared to RELAPSE
cells. Similarly, the combination of CDK4/6 inhibitor abemaciclib (50 nM) with CDK2/7/9 and CSK2
inhibitors (SNS-032 50 nM; CX-4945 1500 nM) decreased cell proliferation significantly only for the
REL_FREE cells (p = 0.008) (Figure 4f). The RELAPSE cells showed significant antiproliferative effect
only when exposed to a high concentration (15000 nM) of CX-4945 inhibitor.
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Figure 4. The effect of inhibitors of V-ATPases, casein kinase 2 (CSK2) or cyclin-dependent kinases
(CDKs) on AML cell proliferation. AML patient cells were treated for six days with the indicated
inhibitors. The thymidine incorporati n-based proliferation measurements re pres nted as dots
(purple for RELAPSE and green for REL_FREE) in patient groups or in individual patient curves.
Significance of inhibitor treatment between patient groups and of inhibitor treatment vs. untreated
control was found using the Mann–Whitney U test and the Wilcoxon matched-pair signed rank test,
respectively. Non-significant results are indicated with “p = ns”. (a) Viability of cells relative to
untreated control for RELAPSE and REL_FREE groups, when treated with 10 nM of V-ATPase inhibitor
Bafilomycin A1 (BafA1). (b) Differences of cell proliferation relative to control for RELAPSE and
REL_FREE groups when treated at 1, 5 and 10 nM BafA1. (c,d) Cells from four REL_FREE and seven
RELAPSE patients treated with BafA1. The RELAPSE, but not the REL-FREE, patients had decreased
proliferation (measured after 6–7 days of culture) when treated with 10 nM BafA1 inhibitor compared
to control, 1 and 5 nM. Non-significant change was observed between control and 1 nM or 5 nM BafA1
inhibitor for either groups. (e,f) Cells from nine REL_FREE and ten RELAPSE patients (five and four of
them were external to the patient cohort, respectively) were treated with CSK2, CDK2/7/9 and CDK4/6
kinase inhibitors in cell proliferation assays, alone or in combination. The CSK2 inhibitor CX-4945 was
given at 0 (i.e., control), 5000 and 15000 nM alone. The CDK4/6 inhibitor Abemaciclib (50 nM) was
given in combination with i) the CDK2/7/9 inhibitor SNS-032 (50 nM) and ii) CX-4945 (1500 nM). The
same RELAPSE patient with high cell proliferation is represented with an asterisk (*).
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These cell proliferation studies with the kinase inhibitors showed that the RELAPSE group
included an exceptional patient (marked with * in Figure 4e,f). When leaving this patient out from the
statistical comparison of CX-4945 monotherapy, the same differences remained statistically significant
as when all patients were included (see Figure 4e right part). However, when analyzing the effects
of abemaciclib combinations without this exceptional RELAPSE patient, we obtained a p value of
0.008 for the inhibitor-free control vs. abemaciclib + SNS-032, whereas this p value was not significant
0.059 if all RELAPSE patients were included (see Figure 4f right part). Furthermore, a p value of 0.038
was seen if this patient was excluded from the comparison of inhibitor-free control vs. abemaciclib
+ CX-4945 (not significant when all RELAPSE patients were included, see Figure 4f right part).
AML is a heterogeneous disease and the detection of single exceptional patients is, in our opinion,
expected. However, even when leaving out this exceptional RELAPSE patient, the antiproliferative
effects were generally stronger for REL_FREE than for RELAPSE patients when testing abemaciclib +
SNS-032 (median proliferation in percent of the inhibitor-free control cultures being 36% with range
11–97% for REL_FREE vs. median 41% with range 10–72% for RELAPSE patients) and abemaciclib
+ CX-4945 (median 41% with range 19–85% for REL_FREE vs. median 63% with range 17–104% for
RELAPSE patients).
Western blot analyses using lysates from three RELAPSE and three REL_FREE patient cells
incubated with media (control) or CDK2/7/9 or ERK1/2 inhibitors showed both higher CDK2 expression
and higher phosphorylation on T160 in the RELAPSE group, although differences between groups
were only significant for the phosphorylated protein in the control samples and after treatment with
SNS032 inhibitor (Figure S13b). SNS032, a compound that targets the kinase catalytic ATP-binding
pocket [50], did not affect CDK2 T160 phosphorylation in any group, although this might be due to the
short incubation time (15 min) used in the experiment [51,52]. The phosphorylation of ERK1/2 was low
and similar in the two patient groups. SCH772984, an ATP-competitive compound of ERK1/2 [53],
decreased kinase activity similarly in the RELAPSE and REL_FREE samples. These findings correlate
with the phosphoproteome analyses, showing a higher relative abundance of phosphorylated CDK2
substrates, but not of ERK1/2 substrates, in the RELAPSE group.
3. Discussion
Chemoresistant disease (i.e. primary resistance or chemoresistant relapse) is a major cause of
death in AML [8]. In this study, we compared the proteomic profiles at the time of first diagnosis for
patients with later relapse and patients without leukemia relapse, after an observation time of at least
five years from the initial intensive and potentially curative induction and consolidation therapy.
Many of the statistically significant proteomic differences between patients with and without
leukemia relapse were relatively small, and for this reason we did not only focus on statistically
significant differences of single proteins, but also on proteomic/phosphoproteomic profiles and
the similarities in biological functions for groups of differing proteins. However, we want to
emphasize that the biological significance of the observed proteomic differences can only be proven by
additional empirical testing. Furthermore, our present study should be regarded as a population-based
study; treatment-related mortality or morbidity do not influence our results because we excluded
those patients who died from or could not complete the planned intensive treatment due to severe
treatment-related toxicity.
A detailed methodological discussion is therefore necessary to ensure correct and careful
interpretation of our results. Our study included patients with a relative high percentage of AML
blasts among circulating leukocytes. This selection was necessary to prepare highly enriched AML
cell populations by a simple and standardized gradient separation alone. This strategy was chosen
because more extensive cell separation procedures can alter the molecular profiles of AML cells.
The possible consequences of these alterations have been discussed in detail previously [54,55].
Firstly, we previously compared the characteristics of patients selected according to these criteria
(corresponding to approximately half of the consecutive patients), with the other patients without
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high peripheral blood blast counts during a defined time period, and we could not detect any
significant differences with regard to karyotype or FLT3 mutations [56]. Secondly, in a previous
study including 71 patients selected according to these criteria, we observed an expected frequency
of various submicroscopic mutations in 54 genes frequently mutated in AML [12–14,34], that is also
recognized in our present patient cohort (Table S1). Finally, our two patient subsets with and without
relapse after completed intensive therapy are defined by very simple criteria, and the observation
time used to define relapse-free patients is long. Thus, our population-based patient cohort does
not differ from other larger AML patient cohorts, with regard to karyotypes and submicroscopic
mutational frequencies, and the two patient subsets are defined by simple criteria based on in vivo
chemosensitivity. Moreover, the association between proteomic patterns and clinical indicators such
as genetic mutations and cytogenetics has been recently shown to be limited in AML suggesting
proteomic-defined signatures as independent prognostic factors [57]. Therefore, further stratification
analysis of the AML samples based on their FAB classification or genetic mutations might not provide
additional prognostic information.
The peripheral blood blast level may have an adverse prognosic impact in AML patients receiving
intensive chemotherapy, although this impact is very weak compared with karyotype and genetic
abnormalities [58]. In a previous HOVON/Sakk clinical study, leukocytosis exceeding 2 × 109/L was
regarded as a risk factor for patients with t(8;21) [59], but this could not be confirmed in a recent separate
study [60]. Furthermore, the most recent ELN guidelines do not recommend the use of peripheral
blood blast counts in the prognostic evaluation of AML patients either [8]. Despite the similarities
in genetic abnormalities, it can therefore be argued that we studied a patient cohort with increased
chemoresistance compared with AML in general, and not only for patients with high blood blast
counts. Recent studies also suggest that the leukocyte count may have a prognostic impact, but only in
the small subset of patients with leukocyte counts exceeding 50 or even 100 × 109/L [59,61,62]. Only six
out of our 41 patients had leukocyte counts exceeding 100 × 109/L and most patients had counts below
50 × 109/L. Thus, we cannot exclude that the observations in our present in vivo chemotherapy study
are representative only for patients with circulating AML blasts, but our selection of patients with a
high percentage of circulating blasts probably represents only a minor difference from AML in general
with regard to in vivo chemosensitivity.
Our proteomic and phosphoproteomic study was based on peripheral blood and not bone marrow
cells, even though AML is by definition a bone marrow disease [2], but for several reasons we regard
peripheral blood cells to be relevant. First, flow cytometric studies of molecular profiles have only
detected limited quantitative but not qualitative differences between peripheral blood and bone
marrow cells from the same patients [63]. Recently, the reverse phase protein array (RPPA)-based
proteomic profiling of blood-derived AML samples were found to be similar to that of marrow-derived
samples [57]. Second, the fundamental AML associated genetic abnormalities are also detected in
the peripheral blood cells. Third, peripheral blood cells also have a hierarchical organization and
include cells capable of long-term in vitro proliferation (i.e., leukemic stem cells) [64] and functional
comparisons of blood and bone marrow AML cells from the same patient also suggest that they show
relatively small differences [65]. Finally, the definition used for most patients for the diagnosis of AML
is the detection of at least 20% blasts in the bone marrow [2]. More extensive cell separation procedures
would therefore be required to achieve highly enriched AML bone marrow cell populations and such
separation procedures may then alter the cell characteristics [55].
The final methodological question is the use of cryopreserved total AML cell populations for
our studies. Even though cryopreservation and thawing would be expected to influence proteomic
and phosphoproteomic profiles in AML cells, our previous methodological studies with comparison
of paired (i.e., both samples derived from the same patient) cryopreserved and fresh AML cell
samples suggested that this influence is limited [31]. All samples in our study were cryopreserved
by using the same standardized technique and without any difference in storage time between our
two patient subsets. Furthermore, both our present in vivo chemotherapy study and several previous
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patient studies have demonstrated that the biological characteristics of the total hierarchical AML
cell population reflect the risk of relapse (i.e., the chemosensitivity), both with regard to genetic
abnormalities as well as constitutive in vitro cytokine release, global and stem cell gene expression
profiles, epigenetic characteristics and intracellular pathway activation [12–14,66–72]. Thus, even
though leukemic stem cells are regarded as responsible for AML relapse [73], biological characteristics
associated with relapse risk are also reflected in the total AML cell population.
Despite the patient heterogeneity, significant overall differences were observed at the proteome
and phosphoproteome level for several biological processes between AML cells from RELAPSE and
REL_FREE patients, harvested at the time of diagnosis. In particular, proteins involved in ribosome
biogenesis and rRNA processing/regulation were more abundant and more strongly phosphorylated in
RELAPSE patient cells. This finding of rRNA processing upregulation was supported by the ChIP-seq
data analysis from the K562 cell line, where we found several transcriptions factors promoting the
transcription of genes for RNA polymerase (CEBPZ) and ribosome/ribosomal biogenesis (PML, AFF1,
ETV6 and TRIM28). Deregulated RNA binding proteins and ribosome biogenesis can be drivers of
cancer pathogenesis [74,75]. Furthermore, the GSEA analysis revealed enrichment of MYC targets in
RELAPSE patients. MYC is frequently overexpressed in AML as well as other leukemic malignancies,
and seems to be a crucial transcriptional factor during hematopoiesis [76,77]. MYC is also a regulator
of ribosome biogenesis [78], activates RNA pol I for rDNA transcription [79] and induces snoRNA
expression [80]. As MYC targets are enriched during relapse, our findings suggest that MYC, together
with proteins involved in rRNA processing and ribosome biogenesis, are prognostic biomarkers for
relapse and potential therapeutic targets in AML. Several drugs targeting rRNA synthesis, transcription
or processing in hematological cancers have already been described [81,82].
We observed an increased abundance of V-ATPase subunits in REL_FREE patients. The
V-ATPase complex can modulate several intracellular signaling pathways with importance in AML
(such as PI3K-mTOR [83,84], NOTCH1 [85] and WNT [86]) by controlling acidification of intracellular
compartments. V-ATPase is also important for autophagy [87]. Two previous studies have described
an association between low expression at the mRNA level of single autophagic regulators and an
adverse prognosis. First, BECN1 is important for the initiation and advance of autophagy, and reduced
BECN1 mRNA levels were associated with an adverse prognosis, FLT3-ITD, monosomal karyotype
and high age [88]. Second, decreased BECN1 mRNA expression is also associated with an adverse
prognosis [89]. Thus, our present studies suggest that the expression profile of mediators involved in
autophagy is associated with prognosis in human AML, and to the best of our knowledge our present
study is the first to describe this for several mediators and at the protein level.
When testing the effect of V-ATPase inhibitor on AML cells, we observed that the RELAPSE derived
cells with initially low abundance of V-ATPase subunits responded better to BafA1 V-ATPase inhibitor,
thus, a potential relationship between low initial V-ATPase subunit abundance and chemoresistance
needs further evaluation. V-ATPase is regarded as a potential therapeutic target in AML [90]. The
role of autophagy in AML is complex. Autophagy is often reduced in human AML cells and the loss
of key autophagy genes leads to leukemia initiation and progression in mouse models [91]. On the
other hand, autophagy seems important for the pro-survival protection of AML cells, and exposure
of the leukemic cells to antileukemic drugs (i.e., cytarabine, anthracyclines and sorafenib) seems to
activate and increases autophagic flux and thereby allowing them to resist chemotherapy [92–95].
These different roles suggest that the effect of therapeutic targeting of autophagy in human AML will
differ between patients, and this is also consistent with our present data.
Upregulated iron transport and vesicle proteins were enriched in REL_FREE patients. In an
independent study, AML patients with high constitutive cytokine release showed increased mRNA
expression of proteins involved in intracellular iron homeostasis and molecular trafficking [66].
Interestingly, the overall survival after intensive chemotherapy was significantly higher for high-release
compared with low-release AML patients. These results provided confidence and an internal validation
of our approach.
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Alignment of sequences surrounding phosphorylation sites and KSEA analysis of our full
phosphoproteomics dataset showed an enrichment of phosphorylated substrate groups of MAPK,
CSK2, CDK, PAK, PRKC and AKT kinases. We additionally observed that RELAPSE cells had higher
activity of CDK2 and higher expression, based on immunoblotting assays, compared to REL_FREE
cells. As similarly demonstrated previously, KSEA of phosphoproteome data of AML-derived cells
from 20 patients had similar enrichment of CSK2, CDK, PAK, AKT, ABL, SRC, MAPK, PRKA and
PRKC kinases, relative to normal peripheral blood stem CD34+ cells from five healthy donors [45].
Thus, two independent phosphoproteomics studies on different AML patient cohorts have identified
similar sets of kinase upregulations in AML.
The CSK2 inhibitor CX-4945 had a stronger antiproliferative effect for REL_FREE cells than
for RELAPSE cells, when acting alone or in combination with CDK inhibitors. Further studies are
required to determine whether RELAPSE cells owe their higher CSK2 inhibitor resistance to generally
increased robustness or to the lower turnover of CSK2-mediated phosphorylation. Comprehensive
KSEA, sequence logos and antibody blotting analyses show that CSK2 and CDKs could be suggested
as strong RELAPSE promoters. CSK2, in particular, is a key regulator of several signaling networks
and is overexpressed in many hematological cancers [96]. The activity of CDK2 (and potentially also
CDK4, CDK6, CDK7 and CDK9) in RELAPSE patients may further increase AML cell proliferation by
triggering G1-S-phase transitions [97].
Several phosphoproteins were multi-phosphorylated, like BCL11A with several phosphosites
upregulated in the RELAPSE group (S205, T208, S608, S625, S630 and S718). BCL11A, a transcription
factor associated with the BAF SWI/SNF chromatin remodeling complex, may play a role in
leukemogenesis [98] and its expression is associated with adverse outcome in AML [99]. In a
previous phosphoproteomics study with AML patients treated with the FLT3 inhibitor quizartinib,
increased phosphorylation of BCL11A S630 was associated with non-responsiveness [27]. Taken
together, these results suggest that BCL11A phosphorylation contributes to chemoresistance in AML.
TP53BP1, another multi-phosphorylated protein in RELAPSE patients, is a double-strand DNA break
repair protein that is phosphorylated at multiple sites in response to DNA damage. Moreover,
phosphorylation at S1219 by ATM kinase seems to be a response to ionizing radiation [100]. The S523Q
motif might also serve as substrate for ATM kinase and being part of the RIF1, a non-homologous end
joining-mediated repair protein, recruitment process to DNA break sites [101].
The stimulatory T190 and T191 phosphosites in the activation loop of NEK7 showed increased
phosphorylation in the REL_FREE patients. NEK7 seems to be involved in the recruitment of
centrosomal pericentriolar proteins that are necessary for centriole duplication and spindle pole
formation during mitosis [102]. Chromosomal lagging, micronuclei formation, cytokinesis failure
and tetraploidy/aneuploidy were observed in NEK7 deficient mouse embryonic fibroblasts [103].
Therefore, deregulation of NEK7 activity in cell division processes might contribute to aberrant
mitosis and induction of the relapse status [104]. Furthermore, we found two phosphosites, S372 and
S389, in the ribosomal S6 kinase RPS6KA1 isoform 2 (Uniprot identifier: Q15418-2), upregulated in
REL_FREE patients. It has been reported that phosphorylation at S372 and S389, possibly by PRKC
activators, switched on the RPS6KA1 N-terminal kinase domain required for phosphorylation of its
substrates [105]. The role of ribosomal S6 kinases in cancer is not well understood and seems to vary
by cancer type. While some isoforms of ribosomal S6 kinases can promote cell motility and invasion
processes by altering transcription and integrin activity, others depress them by interacting with the
actin cytoskeleton [106]. The fact that the phosphosites of RPS6KA1 might be phosphorylated by
NEK7 [104], and not by MTOR, might explain the benefits of higher phosphorylation of membrane,
actin filament and cell-cell adherens junction proteins in the REL_FREE group. Our findings encourage
functional studies to understand the role of NEK7, PRKC and RPS6KA1 kinases in the cytoskeleton of
AML cells.
Finally, although the time intervals to define early or late relapse are debatable [41,42], we
subclassified the 26 RELAPSE into 14 EARLY RELAPSE and 12 LATE RELAPSE patients, after setting
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up 12 months from diagnosis to relapse as the mark time to differentiate the two groups. Our results
showed that the rRNA processing and V-ATPase clusters (identified when all the 26 RELAPSE patients
were included) mainly described the proteome landscape at diagnosis for both the EARLY RELAPSE
vs. REL_FREE and LATE RELAPSE vs. REL_FREE subsets. Thus, the AML proteome at diagnosis
for patients with either an early or late relapse does not seem to change dramatically. In contrast,
the different AML phosphoproteome landscapes at diagnosis described in the EARLY RELAPSE vs.
REL_FREE and LATE RELAPSE vs. REL_FREE subsets appear to be influenced by the relapse-free
time of RELAPSE patients. Our results, considering all the 26 RELAPSE patients, are valuable for
therapy decisions at diagnosis. Nonetheless, further studies with diagnostic and relapsed samples at
early and late relapsing episodes might better describe the role of different AML relapse determinants.
4. Materials and Methods
4.1. AML Patients and Sample Collection
Written informed consent was obtained from all patients in accordance with the Declaration of
Helsinki, and the use of human leukemia cells for the present study was approved by the Regional
Ethics Committee (REK III Vest 2013-634). Primary AML cells were collected from the peripheral
blood of 41 patients with relatively high levels of circulating leukemia blasts (>80% of circulating
leukocytes) at the first time of diagnosis, prior to any antileukemic therapy. The peripheral blood
leukocyte counts are given in Table S1. Six of the patients had leukocyte counts exceeding 100 × 109/L
and six additional patients had leukocyte counts between 50–100 × 109/L, whereas most patients
had leukocyte counts below 50 × 109/L. Peripheral blood samples were collected on ACD tubes and
highly enriched AML cell populations (generally >95%) could then be prepared by density gradient
separation alone (Lymphoprep, Axis-Shield, specific density 1.077) [107]. The gradient separation and
cryopreservation were done immediately after sampling, by using the same standardized method for
all patients [31]. Cells were stored in liquid nitrogen until used in the experiments. Flow cytometric
analyses showed that the main contaminating cell population, as expected, was small lymphocytes.
Our department is responsible for the diagnosis and initiation of intensive antileukemic treatment
for all AML patients in a defined geographical area. The patients in the present study represent all
patients within this area and time period who (i) either completed their planned intensive induction
and consolidation therapy or died from primary resistant AML/early chemoresistant relapse during
treatment, (ii) had a high percentage of circulation AML cells in peripheral blood, and (iii) had an
observation time of at least five years. Patients dying from or ending the planned antileukemic therapy
due to severe treatment-related toxicity were not included in our present study. Our patients could
therefore be classified into two contrasting groups: 15 patients were classified as relapse-free based on
the long follow-up period (i.e., REL_FREE patients) and 26 patients as chemoresistant/relapse patients
(i.e., RELAPSE patients), including all patients with primary resistant, early relapse during initial
chemotherapy or late relapse after completed consolidation therapy. Some of the patients in this last
group later received allogeneic stem cell transplantation.
We compared AML cells derived at the first time of diagnosis prior to any antileukemic treatment
(see Supplementary methods) for the two contrasting patient groups, and the samples did not
differ in storage time or the peripheral blood leukocyte counts of the patients at the time of first
diagnosis/sampling. Additional and more detailed patient information is given in Figure 1a,b, Table 1
and Table S1, including the results from karyotyping and mutational analysis of 54 genes frequently
mutated in AML. The method for mutational analyses has been described previously [108]. Mutations
were classified according to their biological function [34].
Nine additional AML patients were included in validation studies and are described in detail in
Table S2.
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4.2. AML Super-SILAC Mix
An AML spike-in reference was generated by combining Arg6- and Lys8-labeled protein lysates
from five heterogeneous AML-derived cell lines, according to the super-SILAC mix approach [30,109].
The spike-in reference was added to each patient sample in a 1:2 ratio (w:w; super-SILAC mix:AML
patient sample) for SILAC-based quantitation.
4.3. Patient Sample Preparation for Proteomic and Phosphoproteomic Analysis
Sample preparation of patient cell lysate in 4% sodium dodecyl sulfate (SDS)/0.1 M Tris-HCl
(pH 7.6) and immobilized metal affinity chromatography (IMAC) has been described earlier [32].
Briefly, 20 µg of each patient lysate was prepared both as 1) a label-free sample and 2) mixed
with 10 µg of the super-SILAC mix for proteomic analyses, and processed according to the FASP
protocol (Figure 1c) [32,110]. Only the super-SILAC spiked peptide samples were fractionated
using styrenedivinylbenzene-reversed phase sulfonate (SDB-RPS) plugs (Empore, 3M) [111]. The
phosphoproteomics samples (64–1121 µg range) were mixed with the super-SILAC mix at the ratio
described before, FASP processed and enriched for phosphopeptides using the IMAC procedure.
4.4. Nanoflow LC-MS/MS
Peptide sample preparation prior to LC-MS/MS and settings of the LC-MS/MS runs on a Q
Exactive HF Orbitrap mass spectrometer coupled to an Ultimate 3000 Rapid Separation LC system
(Thermo Scientific, Waltham, MA, USA) were conducted as described earlier for global proteomics [112]
and phosphoproteomics [32], and detailed in Supplementary Methods.
4.5. Data and Bioinformatics Analysis
LC-MS/MS raw files from RELAPSE and REL_FREE samples were processed with MaxQuant
software version 1.5.2.8 (see Supplementary methods) [113,114]. The spectra were searched against the
concatenated forward and reversed-decoy Swiss-Prot Homo sapiens database version 2018_02, using
the Andromeda search engine [115]. The LC-MS/MS raw files and MaxQuant output files have been
deposited to the ProteomeXchange consortium via the PRIDE partner repository [116,117] with dataset
identifier PXD014997. The Perseus 1.6.1.1 platform was used to analyze and visualize protein groups
and phosphosites [118]. MaxQuant-normalized SILAC ratios were inverted, log2 transformed and
normalized again, using width adjustment. Proteins and phosphosites (localization probability > 0.75)
with at least five individual SILAC ratios in each patient group were selected for two-sample unequal
variance t-test and Z-statistics [119] to find significantly different FC for proteins and phosphosites
between the RELAPSE and REL_FREE groups. Hierarchical clustering of significantly differential
proteins and phosphosites was done with Perseus using the Pearson correlation function and complete
linkage. GO analysis was performed using a GO tool [120]. The most significantly over-represented GO
terms with FDR < 0.05 were displayed in bar plots in Prism8 (GraphPad). Venn diagrams were made
with Venny 2.1 (Oliveros, J.C., http://bioinfogp.cnb.csic.es/tools/venny/index.html) or BioVenn [121].
GSEA (http://software.broadinstitute.org/gsea/index.jsp) was performed against the Hallmark gene set
collection of the Molecular Signatures Database v6.2 [122]. The amino acid distribution surrounding
the phosphosites was analyzed using iceLogo (p = 0.05), with the sequence windows obtained in the
MaxQuant-generated phosphosite output file [43]. Unregulated phosphosites were used as a reference
set. Sequence logo analyses from a small number of phosphopeptide sequences were generated
with WebLogo [46]. Kinase activity estimates were inferred by the KSEA App. [44,45]. Regulated
and unregulated phosphosites were analyzed with the PhosphoSitePlus [123] and NetworKin [124]
databases, using a substrate count and a NetworKin score cutoff of 5. Significantly regulated kinases
with Benjamini–Hochberg adjusted p < 0.05 were showed in bar plots. Kinase activation loop analysis
was performed with the tools for phosphoproteomics data analysis at http://phomics.jensenlab.org.
PPI networks were obtained by using the STRING database version 10.5, with interactions derived
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from experiments and databases at a high confidence score of 0.7 [125]. Networks were visualized
using the Cytoscape platform version 3.3.0 [126]. The ClusterONE plugin was used to identify protein
groups of high cohesiveness [127].
4.6. Enrichment Analysis of Transcription Proteins Binding Sites
Putative binding sites of transcription proteins were found by analyzing public available ChIP-seq
data on K562 cell line (derived from a patient with blast phase chronic myeloid leukemia; an
undifferentiated myeloid cell line also expressing certain erythroid markers [128,129]) at the ENCODE
project [130]. ENCODE accession IDs of files are provided in Table S3. Sequencing reads were
downloaded and aligned to human genome hg19 using Bowtie 2.2.9 [131]. Aligned reads were
subjected to peak calling using MACS and annotated using Homer following methods published
previously [132–136]. Peak information of the putative targets was analyzed by the BETA algorithm
in Cistrome analysis pipeline (http://cistrome.org/ap/root) [137]. A GO enrichment analysis of
putative target genes was carried out using DAVID with default parameters [138,139]. Significantly
over-represented GO terms with Benjamini–Hochberg adjusted p < 0.05 were displayed in bar plots.
4.7. Cell Proliferation Assay
The cytokine-dependent in vitro proliferation of enriched AML cells was analyzed by a
3H-thymidine incorporation assay [56]. Cryopreserved primary cells were thawed in a water bath
set at 37 ◦C and diluted 1:1 with RPMI, containing 2 mM L-glutamine and penstrap. The cells were
incubated at room temperature for 5 min and extra RPMI solution (same volume of the original
cells) was added. The cells were centrifuged at 250× g at room temperature for 8 min and the pellet
was resuspended in 4.5 mL of the RPMI solution. After counting the cells with trypan blue, the
AML cells were seeded in flat-bottomed 96-well microtiter plates (VWR®, Lutterworth, UK), with a
seeding density of 50,000 cells/well (200 µL medium/well). The culture medium was Stem Span SFEM™
(Stem Cell Technologies, Vancouver, Canada), supplemented with granulocyte-macrophage stimulating
factor (GM-CSF), FLT3 ligand (FLT3-L) and stem cell factor (SCF); all cytokines were purchased from
PeproTech (Rocky Hill, NJ, USA) and used at a final concentration of 20 ng/mL. The cells were treated
with 0 (control), 1, 5 and 10 nM BafA1 (Streptomyces griseus—CAS 88899-55-2—Calbiochem, now
Sigma-Aldrich, St. Louis, MO, USA) and the kinase inhibitors (Selleckchem, Houston, TX, USA) at
concentrations indicated in Table S5. All the inhibitors used in this study are well characterized and
more detailed information including clinical trials is available in the PubChem database [140]. After six
days of culture, 37 kBq of 3H-thymidine (Perkin Elmer, Waltham, MA, USA) was added to each well
and the cells were further incubated for 18–20 h, before being harvested and nuclear radioactivity being
measured. For cell viability assay of cells treated with 10 nM BafA1 and control, primary cells were
cultured for 48 h in flat-bottomed 24-well culture plates (VWR®) (1 × 106 cells/mL, 1 mL/well), using
the same medium as described above. The cells were labeled with propidium iodide and fluorescein
isothiocyanate-conjugated Annexin V (Tau Technologies BV, Kattendijke, The Netherlands), prior to
flow cytometry analysis. The percentage of viable, apoptotic and necrotic cells was determined. The
median of triplicate determinations was used in all analyses. A Mann–Whitney U test (SPSS Statistics
v.25, IBM, Armonk, NY, USA) was employed for the analysis of differences between different groups
and Wilcoxon’s matched-pair signed rank test (SPSS Statistics v.25) for the analysis of differences
between paired samples.
4.8. Western Blots
Western blots for three RELAPSE and three REL_FREE patient cells used in the cell proliferation
assay and incubated with kinase inhibitors at 37 ◦C for 15 min were performed. Control and treated
patient primary cells were centrifuged at 270× g at 4 ◦C for 5 min and washed with a solution of NaCl
(9 mg/mL) on ice. After the centrifugation step, 100 µL of 4% SDS/0.1 M Tris-HCl (pH 7.6) were added
to the cell pellets. The samples were heated at 95 ◦C for 7 min and kept in the freezer. Twenty-five
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µg of each sample was loaded on a NuPAGE 4–12% Bis-Tris protein gel (ThemoFisher Scientific) and
transferred onto a nitrocellulose membrane (Amersham Protran, GE Healthcare Life Sciences, Chicago,
IL, USA) in an XCell II Blot Module (ThermoFisher Scientific). Antibodies were purchased from Cell
Signaling Technology (Danvers, MA, USA) and used according to the manufacturer’s guidelines.
Chemiluminescence was measured on a LAS-3000 imager (Fujifilm, Tokyo, Japan). Band intensities for
each protein were determined by densitometry software Image J (Table S6) [141]. Band intensities of a
protein spotted at approximately 17 kDa on Ponceau-stained membranes were used for normalization
(Figure S13a, Table S6). Statistical analysis was performed using unpaired t-test.
5. Conclusions
This study describes the proteomics profiles of patient-derived AML cells collected at the first
time of diagnosis that differ between patients that are long-term relapse free survivors and patients that
relapse. The relapse-associated group displayed decreased expression of V-ATPases and the increased
activity of CDKs and CSK2. Furthermore, our results suggest a subset of transcriptional and metabolic
regulators that could be considered as predictors of prognosis and therapeutic targets in AML.
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